BIOMARK Laboratories-INDIA

www.biomarklabs.com

TECHNICAL SHEET

B1456 CAMPYLOBACTI	CAMPYLOBACTER BOLTEN ENRICHMENT BROTH BASE				
Formula					
Ingredients:	gms/lit.				
Enzymatic digest of animal tissue	10.00				
Lactalbumin hydrolysate	5.00				
Yeast extract	5.00				
Sodium chloride	5.00				
Sodium pyruvate	0.50				
Sodium metabisulfite	0.50				
Sodium carbonate	0.6				
Ketoglutaric acid	1.0				
Hemin	0.01				
Final pH (at 25°C): 7.5 <u>+</u> 0.2					

Directions:

Suspend 13.8 gms. in 500 ml. distilled water. Heat if necessary to dissolve the medium completely. Sterilize by autoclaving at 15lbs pressure (121°C) for 15 minutes. Cool to room temperature and aseptically add reconstituted contents of one vial of Bolten Selective Supplement (BF158) together with sterile 25 ml of lysed horse blood. Mix well and dispense as desired.

Principle:

Enzymatic digest of animal tissue and yeast extract provide growth nutrients. The antibiotic supplement makes the medium selective for the isolation of Campylobacter species. The sample is added in the sterile enrichment broth and may be blended at low speed or stomached and is incubated at 42°C for 48 hours in microaerobic condition. Enrichment culture is further streaked on selective agar for isolation and enumeration. The 5% O_2 , 10% CO_2 and 85% N_2 is the gas combination used. Colonies tend to swarm when initially isolated from clinical specimens.

QC Tests - (I)De	ehydrated Medium						
Colour:		Cream to light ye	Cream to light yellow				
		Homogeneous Fre	Homogeneous Free Flowing powder				
(II)Rehydrated medium							
pH (post auto	claving/heating):	7.5 ± 0.2	7.5 ± 0.2				
Colour (post autoclaving/heating):		A) Basal medium:	A) Basal medium: light amber				
			B) (After addition of blood yields): Cherry red				
Clarity (post	Clarity (post autoclaving/heating):		A) Clear				
,			B) Clear without any precipitate				
(III)O.C. Test	Microbiological						
	acteristics observed after	48 hrs at 42°C (5%O	2 + 10% CO ₂ + 8	35%N ₂)			
MICROORGAN		GROWTH*					
	Campylobacter jeuni (33291)						
	Campylobacter coli (33559)						
	Campylobacter lari (35221)						
	Escherichia coli (25922)						
	Proteus mirabilis (25933)						
	Staphylococcus aureus (25923)						
	Bacillus cereus (10876)						
Bacillus cereus (10876) Inhibite * Key: * = with the addition of supplement		nent					
77.							
Precautions :	1. For Laboratory Use.		L		1		
		2. Follow proper, established laboratory procedures in handling and disposing of					
2. I show properly established laboratory procedures in Harraning and a							

Refer disclaimer Overleaf

infectious materials.

Page 01 of 02

BIOMARK Laboratories-INDIA www.biomarklabs.com

TECHNICAL SHEET

Limitations :	1. Since the nutritional requirements of organisms vary, some strains may be encountered that fail to grow or grow poorly on this medium.						
Use:	For selective enrichment and cultivation of Campylobacter species. Recommended by ISO10272-1:2006						
Storage:	Dehydrated medium- below 30 ° C Prepared mediums- Between 2 to 8°C.						
Packing:	500 gm bottle						
Product profile:	Reconstitution	Quantity on Preparation (500g)	pH (25°C)	Supplement	Sterilization		
B1456	27.6 g/l	18.11 L	7.5 ± 0.2	Sterile 25 ml lysed horse blood and reconstituted contents of 1 vial of Bolten selective supplement (BF158).			

Disclaimer:

User must ensure suitability of the product(s) in their application prior to use. Products conform solely to the information contained in this and other related BIOMARKLABORATORIES publications.

The information contained in this publication is based on our in-house studies and market performance and is to the best of our knowledge true and accurate. BIOMARK LABORATORIES reserves the right to make changes to specifications and information related to the products at any time. Products are not intended for human or animal or therapeutic use but for laboratory, diagnostic, research or further manufacturing use only, unless otherwise specified. Statements contained herein should not be considered as a warranty of any kind, expressed or implied, and no liability is accepted for infringement of any patents.

Page 02 of 02

Rev: December 2020